Identification of Prognostic Markers by Gene Expression Profiling In Myelodysplastic Syndrome Hematopoietic Stem Cells

Identification of Prognostic Markers by Gene Expression Profiling In Myelodysplastic Syndrome Hematopoietic Stem Cells

Show other versions (2)

Bibliographic Details
Main Authors:	Pellagatti, A, Cazzola, M, Giagounidis, A, Perry, J, Malcovati, L, Della Porta, MG, Jadersten, M, Killick, S, Vyas, P, Lindberg, E, Boultwood, J, Wainscoat, J
Format:	Conference item
Published:	2010

Similar Items

Identification of Prognostic Markers by Gene Expression Profiling In Myelodysplastic Syndrome Hematopoietic Stem Cells
by: Pellagatti, A, et al.
Published: (2010)

Identification of Prognostic Markers by Gene Expression Profiling In Myelodysplastic Syndrome Hematopoietic Stem Cells
by: Pellagatti, A, et al.
Published: (2010)

Deregulated Gene Expression Pathways in Myelodysplastic Syndrome Hematopoietic Stem Cells
by: Pellagatti, A, et al.
Published: (2009)

Identification of gene expression-based prognostic markers in the hematopoietic stem cells of patients with myelodysplastic syndromes.
by: Pellagatti, A, et al.
Published: (2013)

Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells.
by: Pellagatti, A, et al.
Published: (2010)

Marked down-regulation of nucleophosmin-1 is associated with advanced del(5q) myelodysplastic syndrome
by: Pellagatti, A, et al.
Published: (2011)

Marked down-regulation of nucleophosmin-1 is associated with advanced del(5q) myelodysplastic syndrome.
by: Pellagatti, A, et al.
Published: (2011)

Frequent Mutation of the Polycomb-Associated Gene ASXL1 in the Myelodysplastic Syndromes and in Acute Myeloid Leukaemia
by: Boultwood, J, et al.
Published: (2009)

Gene Expression Profiling of CD34(+) Cells in Patients with Myelodysplastic Syndromes
by: Pellagatti, A, et al.
Published: (2008)

Marked downregulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes.
by: Pellagatti, A, et al.
Published: (2009)

Expression profiling of CD34+cells in patients with myelodysplastic syndromes: Involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype.
by: Pellagatti, A, et al.
Published: (2006)

Expression profiling of CD34+cells in patients with myelodysplastic syndromes: differences between early and advanced cases and analysis of apoptosis-related genes
by: Pellagatti, A, et al.
Published: (2007)

Haploinsufficiency of RPS14 in 5q- syndrome is associated with deregulation of ribosomal- and translation-related genes.
by: Pellagatti, A, et al.
Published: (2008)

Haploinsufficiency of RPS14 in 5q- syndrome is associated with deregulation of ribosomal- and translation-related genes (British Journal of Haematology (2008) 142, (57-64))
by: Pellagatti, A, et al.
Published: (2009)

Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia.
by: Boultwood, J, et al.
Published: (2010)

COMPREHENSIVE ANALYSIS OF MUTATION STATUS, GENE EXPRESSION PROFILES, BLOOD AND BONE MARROW COUNTS AND OUTCOME IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES
by: Pellagatti, A, et al.
Published: (2014)

Expression profiling of CD34+cells in patients with myelodysplastic syndromes with and without a del(5q)
by: Pellagatti, A, et al.
Published: (2005)

Gene expression profiling of CD34+ cells in patients with the 5q- syndrome.
by: Boultwood, J, et al.
Published: (2007)

Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype.
by: Pellagatti, A, et al.
Published: (2006)

Genome-wide analysis of copy number change and loss of heterozygosity in myelodysplastic syndrome with del(5q) using high-density SNP arrays
by: Wang, L, et al.
Published: (2007)

The role of the iron transporter ABCB7 in refractory anemia with ring sideroblasts
by: Boultwood, J, et al.
Published: (2008)

Genome-wide analysis of copy number changes and loss of heterozygosity in myelodysplastic syndrome with del(5q) using high-density single nucleotide polymorphism arrays.
by: Wang, L, et al.
Published: (2008)

Haploinsufficiency of RPS14 and Deregulation of Ribosomal- and Translation-Related Genes in MDS Patients with Del(5q)
by: Pellagati, A, et al.
Published: (2008)

Lenalidomide selectively inhibits in vitro growth of the malignant clone in myelodysplastic syndrome (MDS) patients with 5q deletion.
by: Jadersten, M, et al.
Published: (2005)

Gene expression profiling in the myelodysplastic syndromes.
by: Pellagatti, A, et al.
Published: (2005)

Identification of aberrant splicing events in myelodysplastic syndrome patients with splicing factor gene mutations
by: Pellagatti, A, et al.
Published: (2017)

High-resolution genomic profiling of myelodysplasia (MDS) by microarray comparative genomic hybridization (CGH).
by: Esoof, N, et al.
Published: (2006)

Expression profiling of CD34+cells in patients with myelodysplastic syndromes with and without a del(5q).
by: Pellagatti, A, et al.
Published: (2004)

The role of the iron transporter ABCB7 in refractory anemia with ring sideroblasts.
by: Jacqueline Boultwood, et al.
Published: (2008-04-01)

Targeted re-sequencing analysis of 25 genes commonly mutated in myeloid disorders in del(5q) myelodysplastic syndromes.
by: Fernandez-Mercado, M, et al.
Published: (2013)

Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.
by: Malcovati, L, et al.
Published: (2011)

GFI1(36N) as a therapeutic and prognostic marker for myelodysplastic syndrome (MDS)
by: Botezatu, L, et al.
Published: (2016)

Clonality in the myelodysplastic syndromes.
by: Boultwood, J, et al.
Published: (2001)

Frequent Mutation of the Polycomb-Associated Gene ASXL1 In Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
by: Fernandez-Mercado, M, et al.
Published: (2010)

Molecular pathogenesis of the myelodysplastic syndromes
by: Boultwood, J, et al.
Published: (1999)

Lenalidomide up-regulates SPARC and inhibits in vitro growth of the malignant clone in myelodysplastic syndrome patients with 5q deletion.
by: Pellagatti, A, et al.
Published: (2006)

High and low, but not intermediate, PRAME expression levels are poor prognostic markers in myelodysplastic syndrome at disease presentation.
by: Liberante, F, et al.
Published: (2013)

High and low, but not intermediate, PRAME expression levels are poor prognostic markers in myelodysplastic syndrome at disease presentation
by: Liberante, F, et al.
Published: (2013)

Gene expression profiling of day 7 erythroblasts from RARS before and after treatment with G-CSF
by: Nikpour, M, et al.
Published: (2007)

SF3B1 mutant myelodysplastic syndrome: Recent advances
by: Pellagatti, A, et al.
Published: (2020)